Find uplifting stories about heroes, innovations, and solutions
5 results for "kras inhibitor"
A breakthrough drug called daraxonrasib targets the "undruggable" mutation behind 90% of pancreatic cancers, nearly doubling survival time in a major clinical trial. Patients lived 13.2 months compared to 6.7 months with standard chemotherapy.
A breakthrough drug called daraxonrasib is giving hope to pancreatic cancer patients after scientists spent nearly 50 years trying to target the KRAS mutation. Patients like 36-year-old Leanna Stokes are living far longer than expected thanks to this medical breakthrough.
University of Pennsylvania researchers eliminated precancerous pancreatic cells in mice before they became tumors, nearly doubling survival time. It's the first proof that medical intervention can stop pancreatic cancer at its earliest stage.
After decades of slow progress, breakthrough drugs targeting a genetic mutation found in 90% of pancreatic cancers are nearing FDA approval in 2026. The KRAS inhibitors now in late-stage trials could transform treatment for one of medicine's deadliest diseases.
A new triple therapy treatment completely eliminated pancreatic tumors in mice, offering hope for one of the deadliest cancers. The breakthrough could transform treatment for the 67,000 Americans diagnosed each year.